GlassScriptPhysician profile
Nisreen Kothari
NPI 1730445644
$1,589.03
in general payments reported to CMS, 2019-2025
17 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $181 · 2021: $98.50 · 2022: $309 · 2023: $271 · 2024: $240 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.05 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $289.48 | 2019-2025 | Rocklatan, Clareon, Acrysof Iq Panoptix Uv Iol |
| Abbvie INC. | $210.04 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $194.56 | 2019-2023 | |
| Allergan, INC. | $178.18 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $143.41 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $103.43 | 2022-2025 | Tyrvaya, Ryzumvi, Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $93.86 | 2019-2022 | |
| Thea Pharma INC. | $63.37 | 2023-2025 | Iyuzeh |
| Bausch & Lomb Americas INC. | $59.61 | 2022-2023 | Miebo, Lotemax Sm, Alrex |
| Astellas Pharma US INC | $57.65 | 2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $43.75 | 2022-2024 | |
| Aerie Pharmaceuticals, INC. | $41.69 | 2020-2021 | |
| Sight Sciences, INC. | $35.50 | 2019 | |
| Shire North American Group INC | $24.09 | 2019 | |
| Biotissue Holdings INC. | $19.27 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $16.92 | 2019 | |
| Horizon Therapeutics Plc | $14.22 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisreen Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.